First Header Logo Second Header Logo

Connection

Anthony Atala to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Anthony Atala has written about Prostatic Neoplasms.
Anthony Atala
Connection Strength
23.935
Prostatic Neoplasms
  1. Atala A. Re: The Proteogenomic Landscape of Curable Prostate Cancer. J Urol. 2019 10; 202(4):664.
    View in: PubMed
    Score: 0.506
  2. Atala A. Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. J Urol. 2019 09; 202(3):460-461.
    View in: PubMed
    Score: 0.503
  3. Atala A. Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. J Urol. 2019 08; 202(2):214.
    View in: PubMed
    Score: 0.500
  4. Atala A. Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. J Urol. 2019 08; 202(2):213-214.
    View in: PubMed
    Score: 0.500
  5. Atala A. Re: Targeting FOXA1-Mediated Repression of TGF-ß Signaling Suppresses Castration-Resistant Prostate Cancer Progression. J Urol. 2019 07; 202(1):36.
    View in: PubMed
    Score: 0.497
  6. Atala A. Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth. J Urol. 2019 07; 202(1):35-36.
    View in: PubMed
    Score: 0.497
  7. Atala A. Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer. J Urol. 2019 05; 201(5):861-862.
    View in: PubMed
    Score: 0.494
  8. Atala A. Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library. J Urol. 2019 05; 201(5):862-863.
    View in: PubMed
    Score: 0.494
  9. Atala A. Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. J Urol. 2019 04; 201(4):668.
    View in: PubMed
    Score: 0.491
  10. Atala A. Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions. J Urol. 2019 03; 201(3):447.
    View in: PubMed
    Score: 0.488
  11. Atala A. Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer. J Urol. 2019 02; 201(2):230.
    View in: PubMed
    Score: 0.486
  12. Atala A. Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics. J Urol. 2019 01; 201(1):33.
    View in: PubMed
    Score: 0.483
  13. Atala A. Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. J Urol. 2018 10; 200(4):701-702.
    View in: PubMed
    Score: 0.467
  14. Atala A. Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer. J Urol. 2018 09; 200(3):501-502.
    View in: PubMed
    Score: 0.463
  15. Atala A. Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. J Urol. 2018 05; 199(5):1115-1116.
    View in: PubMed
    Score: 0.454
  16. Atala A. Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4. J Urol. 2018 04; 199(4):895-896.
    View in: PubMed
    Score: 0.451
  17. Atala A. Re: The Metabolic Co-Regulator PGC1a Suppresses Prostate Cancer Metastasis. J Urol. 2017 12; 198(6):1212-1214.
    View in: PubMed
    Score: 0.442
  18. Atala A. Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer. J Urol. 2017 12; 198(6):1213.
    View in: PubMed
    Score: 0.442
  19. Atala A. Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer. J Urol. 2017 10; 198(4):747.
    View in: PubMed
    Score: 0.436
  20. Atala A. Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis. J Urol. 2017 09; 198(3):485-487.
    View in: PubMed
    Score: 0.433
  21. Atala A. Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer. J Urol. 2017 08; 198(2):259.
    View in: PubMed
    Score: 0.431
  22. Atala A. Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. J Urol. 2017 07; 198(1):102-104.
    View in: PubMed
    Score: 0.428
  23. Atala A. Urological Tissue Cultures. J Urol. 2017 02; 197(2S):S15-S16.
    View in: PubMed
    Score: 0.419
  24. Atala A. Re: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. J Urol. 2017 03; 197(3 Pt 1):701-702.
    View in: PubMed
    Score: 0.419
  25. Atala A. Re: Integrative Analyses Reveal a Long Noncoding RNA-Mediated Sponge Regulatory Network in Prostate Cancer. J Urol. 2017 03; 197(3 Pt 1):701.
    View in: PubMed
    Score: 0.419
  26. Atala A. Re: The Metabolic Co-Regulator PGC1a Suppresses Prostate Cancer Metastasis. J Urol. 2017 02; 197(2):402-403.
    View in: PubMed
    Score: 0.416
  27. Atala A. Re: N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. J Urol. 2016 11; 196(5):1584-1585.
    View in: PubMed
    Score: 0.410
  28. Atala A. Re: Autophagy Defects Suggested by Low Levels of Autophagy Activator MAP1S and High Levels of Autophagy Inhibitor LRPPRC Predict Poor Prognosis of Prostate Cancer Patients. J Urol. 2016 06; 195(6):1948-9.
    View in: PubMed
    Score: 0.398
  29. Atala A. Re: Sex Hormone-Dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. J Urol. 2016 04; 195(4 Pt 1):1168-9.
    View in: PubMed
    Score: 0.394
  30. Atala A. Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression. J Urol. 2016 Mar; 195(3):801.
    View in: PubMed
    Score: 0.390
  31. Atala A. Re: Elf5 Inhibits TGF-ß-Driven Epithelial-Mesenchymal Transition in Prostate Cancer by Repressing SMAD3 Activation. J Urol. 2016 Jan; 195(1):221.
    View in: PubMed
    Score: 0.389
  32. Atala A. Re: PLCe Knockdown Inhibits Prostate Cancer Cell Proliferation via Suppression of Notch Signalling and Nuclear Translocation of the Androgen Receptor. J Urol. 2016 Feb; 195(2):524-5.
    View in: PubMed
    Score: 0.387
  33. Atala A. Re: Regulation of the ITGA2 Gene by Epigenetic Mechanisms in Prostate Cancer. J Urol. 2016 Feb; 195(2):525.
    View in: PubMed
    Score: 0.387
  34. Atala A. Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation. J Urol. 2015 Dec; 194(6):1823-4.
    View in: PubMed
    Score: 0.383
  35. Atala A. Re: The Inhibitor of Differentiation Isoform Id1b, Generated by Alternative Splicing, Maintains Cell Quiescence and Confers Self-Renewal and Cancer Stem Cell-Like Properties. J Urol. 2015 Oct; 194(4):1163.
    View in: PubMed
    Score: 0.379
  36. Atala A. Re: SAHA Triggered MET Activation Contributes to SAHA Tolerance in Solid Cancer Cells. J Urol. 2015 Sep; 194(3):848-9.
    View in: PubMed
    Score: 0.377
  37. Atala A. Re: A Human Prostatic Bacterial Isolate Alters the Prostatic Microenvironment and Accelerates Prostate Cancer Progression. J Urol. 2015 Sep; 194(3):849.
    View in: PubMed
    Score: 0.377
  38. Atala A. Re: Ion Channel TRPM8 Promotes Hypoxic Growth of Prostate Cancer Cells via an O2-Independent and RACK1-Mediated Mechanism of HIF-1a Stabilization. J Urol. 2015 Jul; 194(1):260.
    View in: PubMed
    Score: 0.373
  39. Atala A. Re: Bone-Induced c-Kit Expression in Prostate Cancer: A Driver of Intraosseous Tumor Growth. J Urol. 2015 Jul; 194(1):260.
    View in: PubMed
    Score: 0.373
  40. Atala A. Re: Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. J Urol. 2015 Jun; 193(6):2146-7.
    View in: PubMed
    Score: 0.371
  41. Atala A. Re: Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. J Urol. 2015 Jun; 193(6):2146.
    View in: PubMed
    Score: 0.371
  42. Atala A. Re: Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: II. Role of human ZIP9 in testosterone-induced prostate and breast cancer cell apoptosis. J Urol. 2015 Jun; 193(6):2147.
    View in: PubMed
    Score: 0.371
  43. Atala A. Re: Estrogen receptor ß upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. J Urol. 2015 May; 193(5):1725.
    View in: PubMed
    Score: 0.369
  44. Atala A. Re: Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. J Urol. 2015 Apr; 193(4):1441-2.
    View in: PubMed
    Score: 0.366
  45. Atala A. Re: Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. J Urol. 2015 Apr; 193(4):1442.
    View in: PubMed
    Score: 0.366
  46. Atala A. Re: Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. J Urol. 2015 Jan; 193(1):368.
    View in: PubMed
    Score: 0.361
  47. Atala A. Re: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. J Urol. 2014 Aug; 192(2):613.
    View in: PubMed
    Score: 0.350
  48. Atala A. Re: TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. J Urol. 2014 Jun; 191(6):1927.
    View in: PubMed
    Score: 0.346
  49. Atala A. Re: bispecific small molecule-antibody conjugate targeting prostate cancer. J Urol. 2014 Jun; 191(6):1927-8.
    View in: PubMed
    Score: 0.346
  50. Atala A. Re: Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. J Urol. 2014 Apr; 191(4):1181.
    View in: PubMed
    Score: 0.342
  51. Atala A. Re: enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated salmonella carrying a plasmid co-expressing p53 gene and MDM2 siRNA. J Urol. 2014 Mar; 191(3):866-7.
    View in: PubMed
    Score: 0.339
  52. Atala A. Re: telomere length influences cancer cell differentiation in vivo. J Urol. 2014 Mar; 191(3):867-8.
    View in: PubMed
    Score: 0.339
  53. Atala A. Re: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. J Urol. 2014 Jan; 191(1):270-1.
    View in: PubMed
    Score: 0.336
  54. Atala A. Re: Aire-dependent thymic development of tumor-associated regulatory T cells. J Urol. 2013 Nov; 190(5):1954.
    View in: PubMed
    Score: 0.331
  55. Atala A. Re: p21-activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). J Urol. 2013 Sep; 190(3):1131.
    View in: PubMed
    Score: 0.328
  56. Atala A. Re.: A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. J Urol. 2011 May; 185(5):1976.
    View in: PubMed
    Score: 0.284
  57. Atala A. Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis. J Urol. 2019 02; 201(2):230.
    View in: PubMed
    Score: 0.121
  58. Peak TC, Praharaj PP, Panigrahi GK, Doyle M, Su Y, Schlaepfer IR, Singh R, Vander Griend DJ, Alickson J, Hemal A, Atala A, Deep G. Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochem Biophys Res Commun. 2018 05 23; 499(4):1004-1010.
    View in: PubMed
    Score: 0.115
  59. Atala A. Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. J Urol. 2017 07; 198(1):103.
    View in: PubMed
    Score: 0.107
  60. Atala A. Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse. J Urol. 2017 06; 197(6):1459.
    View in: PubMed
    Score: 0.106
  61. Atala A. Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. J Urol. 2017 01; 197(1):154-155.
    View in: PubMed
    Score: 0.103
  62. Atala A. Re: Bone Metastasis in Prostate Cancer: Recurring Mitochondrial DNA Mutation Reveals Selective Pressure Exerted by the Bone Microenvironment. J Urol. 2016 09; 196(3):957-8.
    View in: PubMed
    Score: 0.101
  63. Atala A. Re: Dietary Flavonoid Fisetin Binds to ß-Tubulin and Disrupts Microtubule Dynamics in Prostate Cancer Cells. J Urol. 2016 08; 196(2):618.
    View in: PubMed
    Score: 0.100
  64. Atala A. Re: RNA-Seq of Single Prostate CTCs Implicates Noncanonical Wnt Signaling in Antiandrogen Resistance. J Urol. 2016 May; 195(5):1621-1622.
    View in: PubMed
    Score: 0.099
  65. Atala A. What's new in urology. J Am Coll Surg. 2004 Sep; 199(3):446-61.
    View in: PubMed
    Score: 0.045
  66. Godbey WT, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 2003 Aug; 10(17):1519-27.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.